May 23, 2022 02:22 PM EDTUpdated 02:36 PM

Delaware court rules against Gilead and Astellas in years-long patent case

Tyler Patchen

News Reporter

A judge in Delaware has ruled against Astellas Pharma and Gilead in a long-running patent case over Pfizer-onwed Hospira’s generic version of Lexiscan.

The case …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Delaware court rules against Gilead and Astellas in years-long patent case

Tyler Patchen

News Reporter

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Delaware court rules against Gilead and Astel­las in years-long patent case

Tyler Patchen

News Reporter

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Delaware court rules against Gilead and Astellas in years-long patent case

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings